Introduction: Up to 30% of HIV infected patients who are receiving HAART do not exhibit a marked increase in the CD4+ T cell count. There is
Introduction
Human immunodeficiency virus (HIV) is a lentivirus; a member of the retrovirus family that causes Acquired Immunodeficiency Syndrome (AIDS) [1] . Human Immunodeficiency Virus
Infection/Acquired Immunodeficiency Syndrome (HIV/AIDS) is among the most serious public health challenges man has ever faced; particularly in developing countries with low per capita income [2] . Approximately 35.0 million people were living with HIV worldwide by the end of 2013 [3] . The number of people receiving HIV treatment has tripled in five years and reached 9.7 million in low-and middle-income countries in 2012, and this represents 65%
of the global target of 15 million people [4] .
Work undertaken by the National Institute of statistics of Rwanda (NISR), in the 2010 RDHS, indicated that in Rwanda, HIV prevalence was 3.7% and 2.2% among women and men, respectively. The city of Kigali, Capital of Rwanda had the highest prevalence (7.3%) in the country [5] . Periodic CD4 count (every three months) and viral load (every 12 months) are used for HIV + patients biological follow up that aims at assessing the infection progression as well as response to HAART [6] . The best limit CD4 count for HAART initiation is 350 cells/μl [7] . Previous studies have showed that factors including age, specific drug regimen, and initial CD4 count influence CD4 count recovery among patients with virological suppression [8] [9] [10] . A low CD4 count before treatment is a risk factor for not achieving a CD4 count > 200 cells/μl following HAART [11] and studies have documented that the lower the CD4 count at HAART initiation; the longer and more difficult it will be to achieve a net CD4+ recovery [12] . HIV+ are said to be undergoing a severe immunosuppression when their CD4 
Results
Demographic characteristics of study participants Table 1 presents the age and sex distribution of study participants.
The mean age was 35 years and about half (47.3%) of the respondents were aged between 31-40 years. More males (57%) than females (43%) participated to the study.
CD4+ cells count at HAART initiation and at 12 months of treatment
As shown in Table 2 CD4 count stratified by sex and age Table 3 presents the levels of CD4+ cells based on sex and age.
Before HAART initiation men had a mean CD4+ count of 109.57 cells/µl and for females the mean was 111 cells/µl. The difference was not significant (P value =0.899). Following 12 months of HAART, the mean CD4+ count among females was higher (311.81 cells/µl) compared to males (299.9 cells/µl). However, this difference was not significant (P value= 0.726). Similarly, there was no difference in CD4+ count between age groups before HAART initiation (P value= 0.536) as well as after 12 months of HAART (P value= 0.584).
Viral load level among study participants
Viral load median was computed at both time points as shown in Table 4 . Median viral load was 23400 HIV RNA copies/ml before HAART. When viral load was expressed in logs for a normal distribution, viral load median was equivalent to 4.3 logs before HAART initiation. After 12 months of HAART; the median viral load dropped to 20 HIV RNA copies/ml (equivalent to 1.3 logs) and the difference in viral load was significant between the two time points (P value = 0.000).
Viral load based on sex and age
Before HAART initiation males had a mean rank viral load 59.9 compared to 49.5 among females but this was not significant (P value= 0.090). Following HAART mean rank of drop in viral load achieved by males was 55.3 and by females 55.8 (P value= 0.766).
Similarly, there was no significant difference between the age and mean rank of viral load before HAART initiation (P value= 0.918) as well as age and mean rank of viral load after 12 months of HAART initiation (P value= 0.063) ( Table 5 ). decrease in viremia to 20 RNA copies/ml while 4 (3.6%) had an increase in their viremia (Table 6) . Younger participants were likely to have lower CD4 count but this was not associated with in increase in viremia and could be attributed to prognostic prediction discrepancies between viral load and CD4 count [6] .
Association between demographics and CD4 count level

Conclusion
We conclude that immune recovery is slow among HIV+ patients who start HAART with severe immunosuppression. Early HAART intervention is necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients. Table 1: Demographic attributes of study participants 
What is known about this topic

Tables
